Cargando…
Safety and efficacy of the Seraph® 100 Microbind® Affinity Blood Filter to remove bacteria from the blood stream: results of the first in human study
BACKGROUND: Bacterial burden as well as duration of bacteremia influence the outcome of patients with bloodstream infections. Promptly decreasing bacterial load in the blood by using extracorporeal devices in addition to anti-infective therapy has recently been explored. Preclinical studies with the...
Autores principales: | Eden, Gabriele, Schmidt, Julius J., Büttner, Stefan, Kümpers, Philipp, Hafer, Carsten, Rovas, Alexandros, Koch, Benjamin Florian, Schmidt, Bernhard M. W., Kielstein, Jan T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9205040/ https://www.ncbi.nlm.nih.gov/pubmed/35715801 http://dx.doi.org/10.1186/s13054-022-04044-7 |
Ejemplares similares
-
In vitro elimination of anti-infective drugs by the Seraph(®) 100 Microbind(®) affinity blood filter
por: Schmidt, Julius J, et al.
Publicado: (2020) -
Interim analysis of the COSA (COVID-19 patients treated with the Seraph(®) 100 Microbind(®) Affinity filter) registry
por: Schmidt, Julius J, et al.
Publicado: (2021) -
Treatment of a Critically Ill COVID-19 Patient with the Seraph 100 Microbind Affinity Filter
por: Pape, Anke, et al.
Publicado: (2021) -
A Multicenter Evaluation of the Seraph 100 Microbind Affinity Blood Filter for the Treatment of Severe COVID-19
por: Chitty, Stephen A., et al.
Publicado: (2022) -
Staphylococcus aureus binding to Seraph(®) 100 Microbind(®) Affinity Filter: Effects of surface protein expression and treatment duration
por: Seffer, Malin-Theres, et al.
Publicado: (2023)